PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Pyrazines”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 829 records · Page 46Linked to original sources

Discovery and validation of a new family of antioxidants: the aminopyrazine derivatives.

Coelenteramine (2-amino-1,4-pyrazine derivative), one of the metabolites of the oxidative degradation of coelenterazine (imidazolopyrazinone derivative), is endowed with excellent antioxidative properties towards ROS/RNS, like its mother-compound. This crucial discovery, made during the study of natural bioluminescent compounds (luciferins), has stimulated the development of synthetic aminopyrazine derivatives as new leads in medicinal chemistry in the field of antioxidant-based therapies. Synthetic approaches, theoretical evaluation, radical scavenging properties in acellular and cellular tests, and in vivo evaluation are described, and illustrated with representative aminopyrazines. Tested compounds were inhibitors of lipid peroxidation and good quenchers of peroxynitrite. They efficiently protect isolated LDL against radical-induced damages. They prevent cell constituents (membranes, DNA) against injuries by various oxidative stressors (UV irradiation, hydroperoxide treatment, oxidized LDL toxicity). Lastly, aminopyrazines are remarkably active in the "hamster cheek pouch" assay (in vivo protection against ischemia-reperfusion damages).

Amidines↗

Effects of azelastine on superoxide anion generation from gamma interferon treated human monoblast cell line U937 measured by chemiluminescence method.

U937 cells are established human monoblast cell line originally isolated from a patient with diffuse histiocytic lymphoma. In the present study, superoxide anion (O2-) generation from U937 cells were measured by 2-methyl-6-[p-methoxyphenyl]-3,7- dihydroimidazo[1,2-a]pyrazin-3-one (MCLA)-dependent luminescence. Addition of 0.5 mumol/l MCLA and a stimulatory agent, such as N-formyl-methionyl-leucyl- phenylalanine (fMLP) and phorbol myristate acetate (PMA), to a suspension of the cells treated with gamma interferon (IFN gamma) caused a marked luminescence which was inhibited by 0.5 mumol/l superoxide dismutase (SOD). On the other hand, the cells which were not treated with IFN gamma caused no significant luminescence by the stimulation with either fMLP or PMA. The adherent IFN gamma-treated cells generated more O2- than the nonadherent IFN gamma-treated cells by the stimulation with fMLP. The maximal luminescence intensity from the adherent IFN gamma-treated U937 cells stimulated by fMLP was dependent upon the number of the cells. Azelastine (A-5610, CAS 58581-89-8) significantly inhibited the O2- generation from the adherent IFN gamma-treated U937 cells stimulated by fMLP or PMA in a dose-dependent manner.

Cell Adhesion↗

Effects of antiallergic drugs on superoxide anion generation from activated human alveolar macrophages measured by chemiluminescence method.

Human alveolar macrophages were recovered by bronchoalveolar lavage and superoxide anion (O2-) generation from the macrophages were measured by 2-methyl-6-[p-methoxyphenyl]-3,7-dihydroimidazo[1,2-a]pyrazin++ +-3-one (MCLA)-dependent luminescence. Addition of 0.5 mumol/l MCLA and a stimulatory agent, such as phorbol myristate acetate (PMA) and N-formyl-methionyl-leucyl-phenylalanine (fMLP), to a suspension of the cells caused a marked luminescence which was inhibited by 0.5 mumol/l superoxide dismutase (SOD). The maximal luminescence intensity was dependent upon the number of the cells. Azelastine (A-5610, CAS 58581-89-8) significantly inhibited the O2- generation from the activated macrophages in a dose-dependent manner. However, the other antiallergic drugs, such as ketotifen, disodium cromoglycate and others showed little effects on the O2- generation from the activated human alveolar macrophages.

Bronchoalveolar Lavage Fluid↗

Renal and antihypertensive effects of a novel eukalemic diuretic, ICI 207,828.

ICI 207,828, an aminomethylphenol pyrazine derivative, produces water diuretic effects with only minimal alterations in kaliuresis in dogs and rats after oral and parenteral administration. In the dog, ICI 207,828 reached maximum activity at a dose of 10 mg/kg, p.o. This was comparable to that of hydrochlorothiazide (HCTZ) at a dose of 5 mg/kg, p.o. or higher. In the rat, a dose of 30 mg/kg, p.o. of ICI 207,828 was comparable to the maximum of water diuretic and saluretic response obtained with HCTZ at a dose of 10 mg/kg, p.o. Based upon studies using in vitro amphibian models of the mammalian nephron, ICI 207,828 appeared to act on both the thick ascending limb of the loop of Henle and the late distal nephron. In the toad bladder preparation, ICI 207,828 inhibited Na+ transport when placed on either the mucosal (amiloride-like) or serosal (thiazide-like or loop diuretic-like) sides. This compound also inhibited Cl- transport in the toad cornea preparation (loop diuretic-like). ICI 207,828 did not change plasma K+ significantly in dogs dosed for 14 days at doses having diuretic effects (5 and 10 mg/kg, p.o., daily). In contrast, HCTZ consistently decreased plasma K+, whereas amiloride increased it significantly. ICI 207,828 demonstrated antihypertensive effects in spontaneously hypertensive rats. At 30 mg/kg, p.o., b.i.d., ICI 207,828 and HCTZ produced approximately equal antihypertensive activities during a 3 1/2-day treatment period. The pharmacological profile of ICI 207,828 indicates that this compound is a potent eukalemic diuretic and antihypertensive agent in animals.

Amiloride↗

[Determination of tetramethylpyrazine in traditional Chinese medicines by high performance liquid chromatography].

This paper reports a method for determining tetramethyl pyrazine in pilules, injections and extracts of Ligusticum chuanxiong by high performance liquid chromatography. The results showed the recovery rate to be higher than 97% and the coefficient of variation (CV) to be 1.39% (with in day) and 1.51% (day to day). The lowest detection amount was 0.005 micrograms. The method was easy, fast and accurate.

Chromatography, High Pressure Liquid↗

Thyroidectomy reduces stress-induced prolactin secretion in rats. Participation of brain serotonergic systems.

Plasma prolactin levels were measured in thyroidectomized and sham-operated rats under immobilization stress. Thyroidectomy significantly reduced prolactin secretion during stress. The pretreatment of thyroidectomized rats with 6-chloro-2-[1-piperazinyl]- pyrazine (MK 212), a serotonin agonist that easily penetrates the blood-brain barrier, reversed the reduction in stress-induced prolactin release in the thyroidectomized group.

Animals↗

Central serotonergic modulation of drinking behavior induced by water deprivation: effect of a serotonergic agonist (MK-212) administered intracerebroventricularly.

The present study was carried out to evaluate the participation of the serotonergic system (5-HT) in the modulation of the drinking response induced by water deprivation. Male Wistar rats implanted with a cannula in the 3rd ventricle were injected with the 5-HT1C/5-HT2 agonist 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) at doses of 0.5, 5, 25, 50 and 125 nmol/2 microliters. MK-212 induced a significant reduction (P less than or equal to 0.05) in water intake over a period of 300 min. This result indicates that the central 5-HT system plays an important role, probably at the level of the periventricular hypothalamus, in the modulation of drinking behavior induced by water deprivation.

Animals↗

Central serotonergic modulation of drinking behavior induced by angiotensin II and carbachol in normally hydrated rats: effect of intracerebroventricular injection of MK-212.

The objective of the present study was to evaluate the role of the central serotonergic (5-HT) system in the modulation of drinking behavior induced by angiotensin II (Ang II) and carbachol. Male Wistar rats implanted with a delay cannula in the 3rd ventricle were injected with the 5-HT1C/5-HT2 agonist 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) (50 nmol/2 microliters) before receiving an intracerebroventricular (icv) injection of Ang II or carbachol (100 ng/2 microliters). MK-212 induced a significant reduction in the drinking response evoked by Ang II or carbachol which was more marked in the case of the cholinergic agonist. The results obtained suggest that thirst and water intake produced by angiotensinergic or cholinergic activation are modulated by the action of 5-HT, possibly at the level of the periventricular hypothalamus.

Angiotensin II↗

Pharmacological characterization of 5-hydroxytryptamine2 and 5-hydroxytryptamine3 receptors in rat dorsal root ganglion cells.

5-Hydroxytryptamine (5-HT) depolarized 87% of the rat dorsal root ganglion cells recorded. 5-HT increased the input resistance (Rin) in 50%, decreased Rin in 41% and produced both responses in 9% of the responding cells. When 5-HT increased the Rin, the response was mimicked by the 5-HT2 agonists alpha-methyl-5-HT, (+/-)-1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane HCl, quipazine and MK 212 (6-chloro-1-[1-piperazinyl]-pyrazine), but not by 2-methyl-5-HT or carboxamidotryptamine. The response to 5-HT was antagonized by ketanserin, spiperone and methiothepin. The unsurmountable blockade induced by higher concentrations of ketanserin was not explained by pseudo-irreversible antagonism or multiple receptor subtypes, but could result from a two-state receptor model or multiple subtypes of the 5-HT2 receptor. This conclusion is supported by the partial agonist action of DOI. Cells responding to 5-HT with depolarization and decreased Rin responded similarly to 2-methyl-5-HT and phenylbiguanide, but not to alpha-methyl-5-HT or carboxyamidotryptamine. This response was surmountably blocked by ICS 205-930 (3-tropanyl-indole-3-carboxylate) (pA2 = 10.3) and MDL 72222 (3-tropanyl-3,5-dichlorobenzoate)(pA2 = 7.8). The arylpiperazines, quipazine and MK 212, antagonized the action of 2-methyl-5-HT with IC50 values of 8 and 4 nM, respectively. These data indicate that 5-HT2 receptors mediate the increased Rin and 5-HT3 receptors mediate the decreased Rin.

Animals↗

Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat.

Previous studies have demonstrated that the 5-hydroxytryptamine1A (5-HT1A) agonist buspirone stimulated rat prolactin (PRL) secretion. Administration of the 5-HT1A agonists gepirone (GEP) or ipsapirone (IPS) s.c. in doses from 1 to 10 mg/kg had no effect on PRL secretion in male rats. However, pretreatment with GEP (10 mg/kg) or IPS (10 mg/kg) significantly attenuated the increase in serum PRL concentration elicited by the 5-HT agonists 5-methoxy-N,N-dimethyltryptamine or 6-chloro-2-(1-piperazinyl)-pyrazine (MK-212). To determine whether the inhibitory effect of GEP or IPS was related to a serotonergic mechanism or a more general inhibitory effect on PRL secretion, the ability of GEP and IPS to inhibit the haloperidol- or alpha-methyl-p-tyrosine-induced increase in PRL secretion was studied. GEP (1, 3 and 10 mg/kg) and IPS (10 mg/kg) inhibited the increase in PRL secretion produced by either haloperidol (0.25 mg/kg) or alpha-methyl-p-tyrosine (75 mg/kg). Furthermore, GEP produced a concentration-dependent inhibition of PRL secretion from anterior pituitary tissue incubated in vitro. The inhibitory effect of GEP was comparable to that of dopamine in this system. Moreover, haloperidol blocked completely the GEP-mediated suppression of PRL secretion in this preparation. These data suggest agonist properties of both GEP and IPS at D2 dopamine receptors. In light of other evidence that GEP has D2 antagonist effects in vivo, we hypothesize that GEP and perhaps IPS are partial dopamine agonists which may contribute to their antianxiety and/or antidepressant properties.

8-Hydroxy-2-(di-n-propylamino)tetralin↗

Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity.

The piperazine-type 5-hydroxytryptamine (5-HT) agonists 1-(m-trifluoromethylphenyl)piperazine (TFMPP), 1-(m-chlorophenyl)-piperazine (m-CPP), 1-(p-chlorophenyl)piperazine (p-CPP) and MK-212 [6-chloro-2-(1-piperazinyl)pyrazine], produced a dose-dependent suppression of spontaneous ambulatory behavior in rats. Pretreatment with the 5-HT antagonists metergoline, methysergide or mianserin, but not selective 5-HT2 or catecholamine antagonists, blocked the reduction of activity caused by TFMPP suggesting that the stimulation of 5-HT receptors was involved in causing this behavioral effect. Other behavioral signs of 5-HT receptor stimulation, such as the 5-HT behavioral syndrome or head-shaking behavior, were not observed in rats injected with TFMPP, m-CPP or MK-212 except at toxic doses. The ability of piperazine agonists to reduce locomotor activity in rats was altered by long-term changes in 5-HT neurotransmission. The destruction of 5-HT neurons by i.v.t. injection of the neurotoxin 5,7-dihydroxytryptamine potentiated the ability of m-CPP to inhibit ambulatory behavior. On the other hand, elevating 5-HT content by administering the monoamine oxidase inhibitors phenelzine or nialamide for 7 days reduced the ability of m-CPP to suppress locomotor activity. Acute administration of the monoamine oxidase inhibitors, or chronic administration of other antidepressants such as desmethylimipramine or iprindole, failed to alter m-CPPs activity-suppressant effects. These studies suggest that chronic changes in 5-HT neurotransmission produce compensatory changes which alter the behavioral response to these piperazine agonists. Taken together with other evidence that both TFMPP and m-CPP are agonists at 5-HT1B and 5-HT1C receptors, the effects of TFMPP and m-CPP on locomotor activity may be associated with the selective activation of 5-HT1C, or possibly 5-HT1B, receptors.

Animals↗

Effects of serotonin receptor agonists and antagonists on schedule-controlled behavior of squirrel monkeys.

The behavioral effects of the serotonin (5-HT) precursor l-5-hydroxytryptophan (l-5-HTP) and the phenylpiperazine 5-HT agonists 6-chloro-2-(1-piperazinyl)pyrazine (MK-212), 1-(m-trifluromethylphenyl) piperazine (TFMPP), 1-(m-chlorophenyl)piperazine (CPP) and 2-(1-piperazinyl)quinoline (quipazine) were compared with those of the putative 5-HT antagonists metergoline, methysergide, cyproheptadine, cinanserin and ketanserin under a multiple 5-min fixed-interval schedule of food or electric shock presentation in squirrel monkeys. Intramuscular administration of l-5-HTP (0.3-17 mg/kg), MK-212 (0.01-1.0 mg/kg), TFMPP and CPP (0.03-10 mg/kg) produced dose-related decreases in responding under both the food- and shock-presentation schedules. Quipazine differed from the other 5-HT agonists in that it increased shock-maintained behavior at doses (0.1-1.0 mg/kg) that decreased responding maintained by food. The 5-HT antagonists produced mixed behavioral effects. Metergoline (0.03-1.0 mg/kg), cyproheptadine (0.1-1.0 mg/kg) and cinanserin (1.0-10 mg/kg) produced dose-related increases in responding maintained by food, whereas only metergoline and methysergide increased behavior maintained by shock presentation. The prototype 5-HT2-receptor ligand ketanserin (0.3-10 mg/kg) differed from the other 5-HT antagonists in that it decreased behavior maintained by either event. Thus, performances maintained by food or shock presentation reveal both qualitative and quantitative differences in the behavioral effects of 5-HT receptor agonists and antagonists.

5-Hydroxytryptophan↗

Cross-resistance of nocodazole-resistant mutants of CHO cells toward other microtubule inhibitors: similar mode of action of benzimidazole carbamate derivatives and NSC 181928 and TN-16.

Stable mutants which are between 1.6- and 2.2-fold resistant to the microtubule inhibitor, nocodazole (NocR mutants) have been isolated in Chinese hamster ovary cells after a single-step selection. The different NocR mutants exhibit specific changes in their cross-resistance or collateral sensitivity toward various microtubule inhibitors (viz. colchicine, podophyllotoxin, taxol, vinblastine, and maytansine), but they show no change in resistance toward unrelated compounds, indicating that the genetic lesions in these mutants are microtubule related. The set of NocR mutants examined and a second-step podophyllotoxin-resistant cell line, PodRII6 (which is highly resistant to nocodazole) were found to exhibit proportionately increased cross-resistance toward various benzimidazole carbamate derivatives (viz. mebendazole, fenbendazole, carbendazim, parbendazole, oxibendazole, albendazole, benomyl, and cambendazole) as well as two additional microtubule inhibitors, NSC 181928 (ethyl 5-amino-1,2-dihydro-3[N-methylanilino)methyl]pyrido [3,4-b]-pyrazin-7-ylcarbamate) and TN-16 [3-(1-anilinoethylidene)-5-benzyl-pyrrolidine-2,4-dione]. These results indicate that the mechanism of action of these latter two inhibitors is very similar to that of nocodazole. The lack of cross-resistance of the NocR and Podrii6 cell lines to thiabendazole provides evidence that the mechanism of action of this compound is different from that of other benzimidazole carbamate derivatives. Based on structure-activity relationship studies between various nocodazole-like compounds, a number of structural features of these compounds which appear important/essential for this type of biological activity have been identified.

Animals↗

The efficacy of praziquantel against cestodes in cats, dogs and sheep.

Praziquantel is a new type of acylated isoquinoline-pyrazine. A single, low oral or subcutaneous dose of the compound is reliably effective against all tested juvenile and adult cestodes in cats, dogs and sheep. Praziquantel is the first cestodicide which is also effective on bile duct cestodes. In cats and dogs, 5 mg praziquantel per kg is completely effective on all stages of Taenia hydatigena, T pisiformis, T ovis, T taeniaeformis, Dipylidium caninum, Mesocestoides corti, Echinococcus multilocularis and E granulosus. Because of its very wide therapeutic index praziquantel is thus particularly suited for eradication programmes, eg, echinococcosis.

Animals↗

Inhibition of adenylate cyclase and stimulation of a high affinity GTPase by the antilipolytic agents, nicotinic acid, acipimox and various related compounds.

In hamster adipocyte ghosts, the influence of the antilipolytic agents, nicotinic acid, 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) and various related compounds, was studied on adenylate cyclase and low Km GTPase activities. As shown before for hormonal factors and nicotinic acid, the new drug, acipimox, inhibited adenylate cyclase by a GTP-dependent process, which was amplified by sodium ions; half-maximal inhibition occurred at about 10 mumol/l acipimox. For the various compounds studied, the following rank order of potency in inhibition of adenylate cyclase was obtained, nicotinic acid greater than 3-carboxy-5-methylpyrazole greater than acipimox greater than 3-carboxy-5-methylisoxazole; 6-hydroxynicotinic acid and beta-pyridylcarbinol had no effect up to 300 mumol/l. In the same membrane system the antilipolytic drugs increased GTP hydrolysis by stimulation of a low Km GTPase as shown before for antilipolytic hormones. The potency order of the antilipolytic agents studied was identical for GTPase stimulation and adenylate cyclase inhibition. The data suggest that the antilipolytic drugs studied act on adipocyte adenylate cyclase via membrane-bound receptors in a hormone-like manner and that stimulation of a high affinity GTPase is involved in the mechanism of adenylate cyclase inhibition by these agents.

Adenylyl Cyclase Inhibitors↗

Gastric antisecretory properties of SCH 32651.

This report describes the gastric antisecretory properties of SCH 32651 (3-amino-2-methyl-8-phenylmethoxyimidazo[1,2-a] pyrazine HCl . 1/3 H2O). In the pyloric ligated rat, SCH 32651 inhibited gastric acid secretion; the oral ID50 (95% confidence limits) was 23.7 (13.8-39.2) mg/kg. In Heidenhain pouch dogs, SCH 32651 antagonized histamine-stimulated acid secretion with an ID50 of 1.44 (0.55-3.91) mg/kg p.o. SCH 32651 was also active against secretory responses to dimaprit, pentagastrin and feeding in dogs. In all test models SCH 32651 showed similar potency to cimetidine. Chronic administration of SCH 32651 or cimetidine caused slight tolerance and its antisecretory effect was readily reversible on cessation of dosing. The data indicate that SCH 32651 is an orally effective novel antisecretory drug.

Administration, Oral↗

Toxicity of morphazinamide compared with pyrazinamide.

In a toxicological study on rats two derivatives of pyrazine: morphazinamide (MZA) and pyrazinamide (PZA) were compared with the objective to verify the possibility of using MZA as a substitute for the hepatotoxic PZA. The daily recorded weight and food intake of the rats were statistically significantly changed in the experimental groups with MZA as well as those with PZA, as compared with the control group and the group fed parallelly, already after the sixth dose of MZA and PZA 2.5 g per kg body weight, and similarly changed were also the various biochemical blood and liver tissue tests. Yet, certain differences were observed between the action of MZA and PZA. Some explanation was obtained from PZA blood and tissue concentrations, determined in the course of 24 hours following the administration of the sixth dose of both drugs. A repeated administration of MZA led to a PZA cumulation in the blood and organs of the rats. The study demonstrated that both drugs are hepatotoxic and, in high doses, also nephrotoxic. Moreover, MZA decreases the concentration of plasmatic iron and causes spleen atrophy. It will not be, therefore, a suitable substitute for the hepatotoxic PZA.

Animals↗

Gastric cytoprotective properties of SCH 32651, a novel antiulcer agent.

The antisecretory activity of SCH 32651 (3-amino-2-methyl-8-phenylmethoxyimidazo[1,2-a] pyrazine HCl . 1/3 H2O) has been described in a preceding paper. This report describes its gastric cytoprotective properties. SCH 32651 inhibited the gastric lesions due to ethanol in a dose-dependent manner (ID50 = 5 mg/kg p.o.) and exerted its maximal effect when given 30 min before ethanol and had a duration of at least 90 min at 30 mg/kg p.o. The activity of SCH 32651 against ethanol was unaffected by indomethacin pretreatment. Furthermore, SCH 32651 produced significant increases in gastric mucus release (10-100 mg/kg p.o.) and rapidly reversed ethanol-induced (30-100 mg/kg p.o.) fall in gastric potential difference (PD). SCH 32651 displayed significant antiulcer activity in indomethacin-(30-100 mg/kg p.o.), aspirin - (30-100 mg/kg p.o.), "aspirin + acid" - (10-100 mg/kg p.o.), reserpine - (10-100 mg/kg p.o.), stress - (30-100 mg/kg p.o.), and cysteamine (10-100 mg/kg p.o.) ulcers. The present data in conjunction with those reported in a preceding paper indicate that SCH 32651 is an orally effective novel antiulcer drug with both gastric antisecretory and cytoprotective properties.

Administration, Oral↗